 Home > Active Ingredient News > Study of Nervous System > Express disease recurrence rate reduced by more than 50%!

Express disease recurrence rate reduced by more than 50%!

 Last Update: 2022-09-09
 Source: Internet
 Author: User

▎Edited by WuXi AppTec Content Team

TG Therapeutics recently announced that its investigational antibody ublituximab targeting the CD20 protein has achieved the primary endpoint in the ULTIMATE I & II Phase 3 clinical trial in the treatment of relapsing multiple sclerosis (RMS) patients.

RMS is a chronic central nervous system demyelinating disease caused by the immune system attacking the myelin sheath that protects nerves, and includes relapsing-remitting multiple sclerosis (RRMS) as well as secondary progressive multiple sclerosis (SPMS)

Image source: 123RF

ULTIMATE I and ULTIMATE II are two independent, randomized, double-blind, active-controlled, global, multicenter Phase 3 clinical trials to examine the efficacy, safety and efficacy of ublituximab compared with the common MS oral drug teriflunomide in patients with RMS.

▲Mr.

Michael S.

▲If you have any business needs, please long press to scan the QR code above, or

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Pregabalin (CNS)

CAS No.: 148553-50-8

Pharmacy Grade

$1/KG FOB

Primidone CAS125-33-7

CAS No.: 125-33-7

Pharmaceutical Grade

$100/KG EXW

API Clomipramine HCl

CAS No.: 17321-77-6

Pharmacy Grade

$40-50/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Express disease recurrence rate reduced by more than 50%!

▎Edited by WuXi AppTec Content Team

▲Mr.Michael S.

▲If you have any business needs, please long press to scan the QR code above, or

▲Mr.

Michael S.